Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 29, 2022

Study Completion Date

December 31, 2025

Conditions

Breast Cancer

Interventions

DRUG

Pembrolizumab

DRUG

Nab-Paclitaxel

Trial Locations (1)

NYU Perlmutter Cancer Center, New York

All Listed Sponsors

lead

NYU Langone Health

OTHER

NCT02752685 - Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter